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Clinical correlates 
of anti‑SARS‑CoV‑2 antibody 
profiles in Spanish COVID‑19 
patients from a high incidence 
region
Robert Markewitz1*, Antje Torge1, Klaus‑Peter Wandinger1, Daniela Pauli1, Andre Franke2, 
Luis Bujanda3,4, José Maria Marimón5, Jesus M. Banales3,4,6, María A. Gutierrez‑Stampa7, 
Beatriz Nafría8 & Ralf Junker1
Laboratory testing for the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) consists of 
two pillars: the detection of viral RNA via rt‑PCR as the diagnostic gold standard in acute cases, and 
the detection of antibodies against SARS‑CoV‑2. However, concerning the latter, questions remain 
about their diagnostic and prognostic value and it is not clear whether all patients develop detectable 
antibodies. We examined sera from 347 Spanish COVID‑19 patients, collected during the peak of 
the epidemic outbreak in Spain, for the presence of IgA and IgG antibodies against SARS‑CoV‑2 
and evaluated possible associations with age, sex and disease severity (as measured by duration of 
hospitalization, kind of respiratory support, treatment in ICU and death). The presence and to some 
degree the levels of anti‑SARS‑CoV‑2 antibodies depended mainly on the amount of time between 
onset of symptoms and the collection of serum. A subgroup of patients did not develop antibodies 
at the time of sample collection. Compared to the patients that did, no differences were found. 
The presence and level of antibodies was not associated with age, sex, duration of hospitalization, 
treatment in the ICU or death. The case‑fatality rate increased exponentially with older age. Neither 
the presence, nor the levels of anti‑SARS‑CoV‑2 antibodies served as prognostic markers in our cohort. 
This is discussed as a possible consequence of the timing of the sample collection. Age is the most 
important risk factor for an adverse outcome in our cohort. Some patients appear not to develop 
antibodies within a reasonable time frame. It is unclear, however, why that is, as these patients differ 
in no respect examined by us from those who developed antibodies.
Currently the world is facing a pandemic of the coronavirus disease 2019 (COVID-19), caused by the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), first detected in Wuhan, China in December  20191. While 
some infections are associated with an asymptomatic clinical course, the spectrum of illness severity among 
symptomatic infections is wide, ranging from mild cases to critical ones with respiratory failure, or dysfunction 
of multiple other organ  systems2–6. The proportion of severe cases as well as the case-fatality rate (CFR) vary 
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widely between different geographic locations, possibly due to different demographics and approaches to testing 
for SARS-CoV-27.
The hallmark of laboratory testing for SARS-CoV-2 in suspected acute cases of COVID-19 is the detection 
of viral RNA via real-time polymerase chain reaction (rt-PCR)8. Over time, different assays for the detection of 
antibodies against different target antigens of SARS-CoV-2 have also become available. While it is widely assumed 
that antibodies against SARS-CoV-2 can be used as a marker for a past or present infection with SARS-CoV-2 
and that they are a marker of immunity against it, many questions surrounding them have not been answered 
definitively:
– Do all patients with PCR-confirmed infections with SARS-CoV-2 develop antibodies, and if not, what does 
that mean for the patients who do or do not develop antibodies? One recent study suggested that up to 30% 
of patients do not develop antibodies after a PCR-confirmed infection with SARS-CoV-29.
– Is the development of antibodies helpful to eradicate the virus or do they even cause harm via immunopatho-
logic mechanisms? There have been recent considerations concerning the possibility of antibody-dependent 
enhancement of SARS-CoV-210
– Can antibodies against SARS-CoV-2 be used as a prognostic marker? And if yes, do they improve or worsen 
a patient’s prognosis?
In order to answer some of these questions, we examined sera from a cohort of Spanish COVID-19 patients 
from a high incidence region, all of whom had PCR-confirmed infections with SARS-CoV-2, for the presence 
of antibodies against SARS-CoV-2. Specifically, we wanted to investigate whether the presence of anti-SARS-
CoV-2 antibodies can be used as a marker of disease severity and what factors correlate with the presence of 
antibodies against SARS-CoV-2.
Methods
Serum samples from 347 Spanish patients from a high-incidence region were collected at one point in time 
(ranging from 0 to 33 days since onset of symptoms) during their stay at the Hospital Universitario Donostia 
(Donostia/San Sebastian, Spain) after they were confirmed to be SARS-CoV-2 positive via rt-PCR, which was 
performed at the Microbiology Service of the Hospital Universitario Donostia. For the rt-PCR, assays from 
three different manufacturers were used: Allplex 2019-nCoV Assay (Seegene Inc, Seoul, South Korea), LightMix 
Modular SARS-CoV-2 (E- gene and RdRP gene) Assay (TibMolbiol, Berlin, Germany) and Viasure SARS-CoV-2 
(ORF1ab and N genes) assay (Certest Biotec, Zaragoza, Spain). Antibody testing was performed at the Institute of 
Clinical Chemistry, at the University Hospital Schleswig–Holstein (Kiel/Lübeck, Germany). The sera were exam-
ined for the presence of IgA and IgG antibodies against the Spike-protein (S1-subunit, including the receptor 
binding domain (RBD)) of SARS-CoV-2 using the Anti-SARS-CoV-2-ELISA kits from EUROIMMUN (Lübeck, 
Germany) according to the manufacturers’ instructions. This test yields a (dimensionless) ratio of the optical 
density (OD) of the sample at 450 nm compared to the OD of a calibrator. Ratios of ≥ 0.8 to < 1.1 are considered 
borderline, ratios of ≥ 1.1 are considered positive. According to the manufacturers’ specifications, testing for anti-
SARS-CoV-2 IgA after more than ten days since onset of symptoms has a sensitivity of 98.6% and a specificity of 
92.0%, testing for IgG a sensitivity of 94.4% and a specificity of 99.6%. The S1-subunit of the Spike-protein was 
chosen as target antigen because of evidence that antibodies against the Spike-protein, especially the RBD, are 
neutralizing and therefore potentially confer  immunity11–13.
Further, the patients’ age and sex were recorded, as was the amount of days that elapsed between the onset of 
symptoms and the collection of the serum sample. Also, as markers of disease severity and outcome, the dura-
tion of the hospital stay, treatment in the ICU, the kind of respiratory support the patient received and death 
were evaluated.
The study was approved of by the Ethics Committee for Clinical Research of Euskadi (CEIC-E) (PI2020064). 
All participants gave written informed consent to all procedure they underwent. For minors under the age of 
18 years, this consent was obtained from the patients’ legally authorized representatives. For patients who died 
in the course of the disease or who were too ill to consent, this consent was also obtained from legally author-
ized persons as mandated by the local ethics committee. The study and all of its’ procedures were conducted in 
concordance with the declaration of Helsinki.
Statistics. Associations between continuous variables were tested for via calculation of the correlation coef-
ficients according to Pearson and Spearman. These results were visualized through a scatterplot for which linear 
regressions as well as their slopes and intercepts were calculated. Differences between groups were tested for 
statistical significance via ANOVA and visualized as combined box and dot plots. Differences were treated as sta-
tistically significant for p-values ≤ 0.05. Levels of significance were indicated in all relevant figures as follows: ns: 
p > 0.05; *: p ≤ 0.05; **: p ≤ 0.01; ***: p ≤ 0.001; ****: p ≤ 0.0001. All data files were processed in the free software 
for statistical computing and graphics R (version 4.0.3) with the integrated development environment RStudio 
(version 1.3.1093)14.
Ethics approval. The study was approved of by the Ethics Committee for Clinical Research of Euskadi 
(CEIC-E) (PI2020064).
Consent to participate. All participants gave written informed consent to all procedure they underwent. 
The study was conducted in concordance with the declaration of Helsinki.
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Results
Sample characteristics. We examined serum samples from 347 patients who were treated at the Hospital 
Universitario Donostia in Donostia/San Sebastian, Spain between March 26th and April 11th and who were 
infected with SARS-CoV-2 as confirmed via PCR. Their mean age was 64.3 years (± 14.1; range: 10–95 years). Of 
the 347 patients, 144 (41.5%) were female and 203 (58.5%) were male. The mean duration of their hospital stay 
was 14.3 days (± 14.4; range: 1–79 days). During their stay at the hospital, 54 patients (15.6%) were treated in the 
ICU and 38 (11%) died. Moreover, 15 patients (4.3%) received no respiratory support, 281 (81%) received  O2 
non-invasively and 51 (14.7%) received invasive ventilation. Of the patients who needed treatment in the ICU, 
13 (24.1%) died. Similarly, of those who needed invasive ventilation the same 13 (25.5%) died. For an overview 
of the patient and sample characteristics, see Table 1.
There was a statistically significant association between age and survival, the mean age of deceased patients 
(75.2 years; ± 10.9) being significantly higher than the mean age of surviving patients (63 years; ± 13.8; p < 0.001; 
see Fig. 1). Furthermore, the CFR rises near-exponentially for each life-decade from 3.2% for 40–49 year old 
patients to 32.6% for > 80 year old patients (see Fig. 2). Conversely, 89.5% of those who died were 60 years of 
age or older. No such relationship was observed for either age or treatment in the ICU or age and duration of 
hospitalization.
Serologic results. Of the 347 samples, 282 (81.3%) were positive or borderline for IgA and/or IgG antibod-
ies against the Spike-protein of SARS-CoV-2 and 65 (18.7%) were overall negative. For a complete overview of 
the numbers and shares of positive samples see Table 2. Sera in which antibodies against SARS-CoV-2 could be 
detected differed from negative sera mainly in one respect: positive samples were collected after a significantly 
longer amount of days since onset of symptoms than negative ones. This is true for both the detection of IgA 
(mean amount of days between onset of symptoms and sample collection: 11.9 days (IgA positive; ± 4.9 days; 
range: 0–30 days) vs. 7·9 days (IgA negative; ± 6.1 days; range: 0–33 days; p < 0.001) and IgG (12.4 days (IgG posi-
tive; ± 4.7 days; range: 0–30 days) vs. 9.2 days (IgG negative; ± 5.8 days; range: 0–33 days); p < 0.001; see Fig. 3). 
For both IgA and IgG positive samples, there is also a statistically significant correlation of medium effect size 
between the amount of days since onset of symptoms and the level of the measured OD ratio (IgA: Spearman 
correlation coefficient: 0.357; p < 0.001; IgG: Spearman correlation coefficient: 0.437; p < 0.001; see Figs. 4 and 5). 
If samples collected on the same day since onset of symptoms are considered collectively, the percentage of IgA 
and IgG positive samples from each day after onset of symptoms describes a steady upward curve until it reaches 
a first maximum of 100% positive samples after 13 days for IgA and 17 days for IgG (see Fig. 6). It is notable, 
however, that even after this point there is a small but persistent amount of samples that remains seronegative 
(IgG: 14 negative samples (4.0%) after day 17 since onset of symptoms; IgA: 9 negative samples (2.6%) after day 
Table 1.  Overview of the patient characteristics; each absolute number is also represented as percentage of 
group defined by the column.
All patients Male female ICU Deceased
Male 203 (58.8%) – – 39 (72.2%) 21 (55.3%)
Female 144 (41.5%) – – 15 (27.8%) 17 (44.7%)
ICU 54 (15.6%) 39 (19.2%) 15 (10.4%) – 13 (34.2%)
Decease 38 (11%) 21 (10.3%) 17 (11.8%) 13 (24.1%) –
Figure 1.  Comparison of the mean age of deceased and surviving patients.
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13 since onset of symptoms) after day 13 since onset of symptoms), most prominently one sample collected 
33 days since onset of symptoms, which is IgA and IgG negative.
Furthermore, there was an association of medium effect size between the detection of IgA and respiratory 
support with non-invasive  O2 (Cramer’s V: 0.31) and the detection of any antibody (IgA and/or IgG) and respira-
tory support with non-invasive  O2 (Cramer’s V: 0.32).
Anti-SARS-CoV-2 positive and negative patients did not differ significantly in age, gender or the duration 
of their hospitalization. There was also no significant association between the serologic status and treatment 
in an ICU or death. For a visualization of these relationships, along with their levels of significance, see Fig. 7. 
Furthermore, only taking into account positive samples, there was no statistically significant difference in the 
measured OD ratio levels between patients who were or were not treated in the ICU, between the different types 
of respiratory support or between patients who did or did not die. There was also no correlation between the 
OD ratio and age.
Since there was a statistically significant impact on the serologic status of the point in time since onset of 
symptoms at which the serum sample was collected, the same statistical analyses were also run for all samples 
that were collected at least ten days since onset of symptoms (which is the amount of time for which the test 
properties are defined by the manufacturer) only. In this subgroup, no associations were found between age, 
duration of hospitalization, treatment in the ICU or death and the serologic status or the value of measured the 
OD ratio. For a visualization of these relationships, see Fig. 8. Of note, the association between the detection of 
antibodies and respiratory support with  O2 only was not observed for the samples collected at least ten days since 
onset of symptoms. Of all these samples, 17 (8.5%) remained negative for both IgG and IgA.
Discussion
Our results demonstrate that the anti-SARS-CoV-2 antibody status strongly depends on the time since symptom 
onset at which the serologic sample is collected. If serum is collected too early after symptom onset, the sensitiv-
ity of the test is considerably decreased. Likewise, at least for IgG, the level of the OD ratio correlates with the 
amount of time since symptom onset. This finding is not surprising as it corroborates findings of other studies 
that the sensitivity of tests for antibodies against SARS-CoV-2 depends on the time since onset of symptoms and 
is especially low in the first  week15,16. It also underscores the important message that the detection of antibodies 
is not suitable for the diagnosis of early stages of COVID-19. Serologic examinations should be ordered at the 
earliest after the amount of time that is recommended in the manufacturers’ instructions, ideally after two to 
three weeks since symptom onset in order to produce meaningful results.
Figure 2.  Case fatality rate (line “deceased”) and share of patients treated in the ICU (line “ICU”) visualized for 
each different life-decade seperately.
Table 2.  Overview of numbers and shares of patients who were tested borderline (bdl.) or positive (pos.) for 
one or both anti-SARS-CoV-2 antibody (ab) classes within the whole cohort and in distinct subpopulations.
IgA bdl IgA pos IgA bdl./pos IgG bdl IgG pos IgG bdl./pos Any ab bdl./pos
All patients 16 (4.6%) 263 (75.8%) 279 (80.4%) 17 (4.9%) 194 (55.9%) 211 (60.8%) 282 (81.3%)
Male 8 (3.9%) 159 (78.3%) 167 (82.3%) 14 (6.9%) 116 (57.1%) 130 (64%) 168 (82.8%)
Female 8 (5.6%) 104 (72.2%) 112 (77.8%) 3 (2.1%) 78 (54.2%) 81 (56.3%) 114 (79.2%)
ICU 0 51 (94.4%) 51 (94.4%) 2 (3.7%) 43 (79.6%) 45 (83.3%) 51 (94.4%)
Deceased 0 25 (65.8%) 25 (65.8 5) 2 (5.3%) 18 (47.4%) 20 (52.6%) 26 (68.4%)
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Figure 3.  Comparison of the mean amount of days from symptom onset until sample collection between 
negative and borderline/positive samples for IgA (top) and IgG (bottom).
Figure 4.  Correlation between the amount of days since onset of symptoms and IgA antibody level.
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Figure 5.  Correlation between the amount of days since onset of symptoms and IgG antibody level.
Figure 6.  Share of samples collected on different days since onset of symptoms that were positive for IgA (top), 
IgG (middle) or either of those (bottom).
7
Vol.:(0123456789)
Scientific Reports |         (2021) 11:4363  | https://doi.org/10.1038/s41598-021-83969-5
www.nature.com/scientificreports/
It is important to note, however, that our results do not indicate that less severe cases of COVID-19 show a 
lower seroprevalence or lower levels of anti-SARS-CoV-2 antibodies, as has been  speculated15. At least in our 
cohort, sensitivity of antibody testing was independent of disease severity.
Figure 7.  Visualization of the relationship between the detection of anti-SARS-CoV-2 antibodies and age 
(A,B), sex (C,D), duration of hospitalization (E,F), treatment in the ICU (G,H) and death (I,J) for all samples of 
our cohort. No statistically significant associations could be found for any of these variables.
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Our results also show that there are some patients who didn’t develop antibodies even after a sufficient 
amount of time. However, those patients do not differ in any phenotype that was examined by us from anti-
SARS-CoV-2 positive patients. Similar observations have been made  before9, but only in a cohort with cases 
of mostly mild to moderate severity. Gudbjartsson et el. also report that even three months after recovery from 
Figure 8.  Visualization of the same analyses as in Fig. 7 for all samples collected at least ten days after onset of 
symptoms. Again, no statistically significant associations could be found.
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a PCR-confirmed infection with SARS-CoV-2, 3.9% of the examined patients remained seronegative for anti-
bodies of all classes against both the S- and the N-protein of SARS-CoV-217. This observation could be due to 
several causes: (1) the PCR that confirmed the infection with SARS-CoV-2 was false-positive, (2) the antibodies 
developed by the patients were directed against another target antigen, (3) some patients might have developed 
a mucosal antibody response in the absence of a systemic response or (4) some patients actually don’t develop 
antibodies against SARS-CoV-2. The first scenario, while theoretically possible, is highly unlikely to account for 
all seronegative cases, given the high specificity of PCR-testing for SARS-CoV-2. The second scenario reveals 
testing for only one target antigen as one of the limitations of our study. Of note however, studies examining the 
antibody responses against different target antigens generally find a good concordance between these responses, 
making this explanation somewhat less  likely17,18. Furthermore, the focus on antibodies against the S1-subunit 
of the spike protein seems prudent to us, as this is also the epitope of neutralizing antibodies (as mentioned 
above). The third scenario falls within the scope of the possible since it has been shown that mucosal antibody 
responses against SARS-CoV-2 can occur in the absence of a systemic response (and even in PCR-negative, 
exposed persons)19. It has to be noted, though, that this constellation was mainly observed in asymptomatic 
cases, whereas our cohort consisted of hospitalized patients, for whom the generally good correlation between 
the mucosal and the systemic response, that has otherwise been  observed18,19, seems more likely to be applicable. 
The fourth scenario, if confirmed, could have important implications for the discussion about immunity against 
SARS-CoV-2. If some patients don’t develop antibodies, irrespective of factors such as age, sex or disease severity, 
are they nevertheless immune against reinfection, mediated e.g. by SARS-CoV-2 specific T-cells? Do the same 
effects apply to vaccination as well and if yes, how is the response to a possible vaccine best measured? These 
questions will have to be urgently answered before any sort of documentation of immunity against SARS-CoV-2 
can be issued as has been  suggested20,21.
In our cohort, neither the levels nor the general presence of anti-SARS-CoV-2 IgA and IgG against the 
S1-subunit of the spike protein determined via ELISA served as a predictor of disease severity as measured by the 
duration of hospitalization, treatment in the ICU or death, nor did we see an influence of gender or age on the 
antibody results. These findings confirm the results of previous  studies16,22 but contradict the findings of others 
that tend to find higher levels of antibodies in men, older patients and more severely afflicted  patients17,23–27. This 
discrepancy in the findings of different studies may be at least partially due to the different serological assays 
used, different makeups of the examined cohorts and different definitions of disease severity. In general, studies 
that examined neutralizing antibody titers found a correlation with disease severity, age and/or  gender22,24,26, 
whereas only some studies using ELISA  did17,24,25,27. Interestingly, the study by Tang et al. found a correlation 
between clinical severity and neutralizing antibody titers, but not for titers of antibodies detected via  ELISA22, 
while the study by Klein et al. found this correlation for both neutralizing antibodies and ELISA  antibodies24. 
In synopsis, while neutralizing antibodies clearly appear to be associated with disease severity, age and sex, this 
relationship is less clear for antibodies detected via ELISA. Of note, depending on the ELISA used, some studies 
found good correlations between neutralizing antibodies and antibodies detected via  ELISA28–30, while others 
found that antibodies detected via ELISA reflected neutralizing activity only  poorly22,24. Part of the explanation 
for this phenomenon is the fact that the titers of neutralizing antibodies have been found to decrease more 
sharply than antibody levels detected via  ELISA24,28. Depending on the point in time since onset of symptoms 
the correlation between neutralization assay and ELISA may therefore be expected to vary with a better correla-
tion at the peak of the antibody response. This is mirrored by the finding that commercial ELISAs (especially 
the one used by us) are particularly useful to detect individuals with high titers of neutralizing  antibodies29,30. 
It is tempting to speculate that we didn’t find a correlation between antibody levels and clinical characteristics 
because the proportion of patients who had reached the peak level of their antibody response was low in our 
cohort. Inversely, this would mean that the peak titer of at least some commercial ELISAs might still be useful as 
a marker of disease severity and outcome, which is supported by the findings of Gudbjartsson et al.17, but more 
data is needed to confirm this hypothesis.
Finally we found higher age to be associated with a worse outcome, as measured by the significantly higher 
mean age of deceased patients as well as the case fatality rate per life decade. This result also supports earlier 
 findings31 and stresses the important message that patients above the age of 60 should be considered to be at a 
higher risk of a complicated course of disease.
Our study has several limitations: Serum has been collected from each patient at a single point in time only, 
in many cases at a time that might have been too early for the detection of antibodies. In some of these individu-
als, a seroconversion might have been observed if the samples had been collected at a later stage or if follow-up 
examinations had taken place. We tried to minimize the effect of this potential bias by analyzing in a second step 
only those samples that were collected at least ten day after onset of symptoms (which is the amount of time for 
which the test properties are defined by the manufacturer). It is notable that we didn’t find any relevant differ-
ences between this subgroup and the whole cohort. Also, all samples were collected from hospitalized patients, 
potentially over representing more severe cases. However, the case-fatality rate of our cohort is 11% and therefore 
comparable to that of all of Spain (9.4%; CFR as of April 11th)32, suggesting that the severity of cases in our cohort 
are at least representative for the Spanish population from which they hail. Another limitation is that we tested 
for antibodies using only one target antigen as well as assays from only one manufacturer. It is possible that the 
patients for whom no anti-SARS-CoV-2 antibodies could be detected using our methods developed antibodies 
against other target antigens. It is noteworthy, however, that studies examining the antibody responses against dif-
ferent target antigens generally found a good correlation between them (as mentioned above)17,18. Furthermore, 
we did not confirm the results of our (commercial) ELISA with a neutralization assay. The relationship between 
antibody levels detected via ELISA and neutralization assays is complex and has been discussed at length above. 
In short, while it is likely that a portion of the antibodies we detected are not neutralizing, results of the ELISA 
we used have been shown to correlate well with the titers of neutralizing antibodies especially at high  levels24,29,30, 
10
Vol:.(1234567890)
Scientific Reports |         (2021) 11:4363  | https://doi.org/10.1038/s41598-021-83969-5
www.nature.com/scientificreports/
making it likely that a considerable share of the antibodies we detected were in fact neutralizing. Nevertheless, 
the results have to be interpreted with due caution.
Also, the PCR-confirmation of SARS-CoV-2 was performed with different assay. This was due to shortages of 
reagents for the SARS-CoV-2-rt-PCR that many laboratories experienced in the initial phase of the pandemic, 
forcing laboratories to diversify their assays.
In conclusion, our findings show that both the general detection of antibodies against SARS-CoV-2 and their 
levels depend largely on the time between onset of symptoms and sample collection and that neither the general 
presence of antibodies nor their levels can be used as a (prognostic) marker of disease severity. Due to the delay 
in the reliable detection of antibodies of two to three weeks since onset of symptoms, commercially available 
serologic assays have little to no value in suspected acute cases of COVID-19. Furthermore, our data appears to 
confirm that some patients don’t develop antibodies against SARS-CoV-2 within the usual time frame as well as 
it shows that those patients differ neither in demographic composition nor in disease severity from their anti-
SARS-CoV-2 positive counterparts.
Questions still remain about possibly seronegative COVID-19 patients: what factors lead to a COVID-19 
patient not developing antibodies (at least against the S1 subunit of the Spike-protein)? Also, our study did not 
examine how long detectable levels of antibodies persist in patients. Both of these questions are of importance 
for considerations of how and when herd-immunity against SARS-CoV-2 can be achieved and will have to be 
addressed in future studies.
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